Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib plus dexamethasone vs bortezomib plus dexamethasone in relapsed multiple myeloma
2012-000128-16Phase 3Completed
- Sponsor
- Amgen
- Start
- Apr 2012
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Carfilzomib plus dexamethasone with Bortezomib plus dexamethasone (2 arms). Primary endpoint: Progression-free survival by Independent Review Committee. Started Apr 2012; status: completed.
02
Drugs
carfilzomibbortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2012-000128-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000128-16.